Download
1 / 7
70 likes | 81 Views
Opdyta 100mg is a prescription drug which is used under the supervision of a doctor, it belongs to a human monoclonal antibody which stops the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
E N D
Apple Pharmaceuticals Is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
Nivolumab injection Opdyta 40mg
DESCRIPTION Opdyta 100mg is prescription drug which is used under supervision of doctor Opdyta 100mg belongs to human monoclonal antibody whichstops the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Opdyta 100mg is an IgG4 kappa immunoglobulin which has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Opdyta 100mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.
INDICATION • MECHANISM • Binding of these ligands to the PD-1 receptor occur on T cells, prohibits T cell multiplication and cytokine production. Upregulation of the PD-1 ligands occurs in some tumor and signallingvia this pathway can provide to prohibition of active T-cell immune surveillance of tumor. Nivolumab belongs to human immunoglobulin G4 (IgG4) monoclonal antibody which binds to the PD-1 receptor and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated prevention of the immune response, containing the anti-tumor immune response, resulting in reduced tumor growth. Opdyta 100mg is indicated for the treatment of patients having : • Melanoma • Non-Small Cell Lung Cancer • Kidney (Renal Cell) Cancer
DOSAGE Opdyta recommended dosage for unresectable or metastatic melanoma: As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity With ipilimumab: The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment For adjuvant treatment of melanoma: As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year. For Non-small cell lung cancer: As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity. For small cell lung cancer : As single agent is either 240mg every 2 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year.
PREGNANCY • LACTATION There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a foetus. • Opdyta 100mg Excretion in human breast milk is not known; advise women to discontinue breastfeeding during treatment
CALL: CONTACT US • +91-9987711567 • EMAIL ID: • applepharamaceutical@gmail.com • ADDRESS: Apartment No.304 A Wing, Shiva Shakthichs ltd, JP Road, Near ApnaBazar,Andheri(West),Mumbai - 400058.Maharashtra.
